Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
AnaptysBio, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, who collectively report beneficial ownership of 813,571 shares of AnaptysBio common stock, representing 2.9% of the outstanding class as of the reported date. The reporting persons disclose shared voting and shared dispositive power over these shares, with no sole voting or dispositive authority.
They state that they now hold 5 percent or less of AnaptysBio’s common stock and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, but instead on a passive basis.
AnaptysBio director Magda Marquet reported an option exercise and related share sales. On January 15, 2026, she exercised a fully vested stock option for 11,000 shares of common stock at an exercise price of $26.11 per share, increasing her direct holdings to 20,930 shares. That same day, she sold 9,290 shares of common stock at a weighted average price of $48.1162 per share, in multiple trades between $47.595 and $48.54, and an additional 1,710 shares at a weighted average price of $48.849 per share, in trades between $48.625 and $48.88. After these transactions, she directly owned 9,930 shares of common stock and held additional options to purchase up to 70,104 shares of common stock that vest according to their terms.
A security holder has filed to sell 11,000 shares of common stock. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around 01/15/2026, with an aggregate market value of $530,531.10 based on the filing.
The 11,000 shares to be sold were acquired on 01/15/2026 through a stock option exercise paid in cash. Shares of the issuer outstanding were 27,688,470, which provides a baseline for the size of this planned sale.
AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity. On January 7, 2026, 8,525 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, reflecting scheduled vesting. The RSU award is set to vest 25% per year starting January 7, 2026, as long as he continues providing services.
On January 8, 2026, he sold 3,650 shares of AnaptysBio common stock at $44.71 per share. The footnotes state this was a “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary sale. After these transactions, he directly held 42,088 shares of common stock and 25,575 RSUs.
This notice under Rule 144 reports that insider Paul F. Lizzul intends to sell 3,650 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC on or around 01/08/2026 on the NASDAQ exchange. The shares come from restricted stock units acquired from the issuer on 01/08/2026, with the purchase price paid in cash.
Over the prior three months, the same seller reported additional sales of the issuer’s common stock: 2,235 shares on 01/07/2026 for gross proceeds of $98,138.85, 4,219 shares on 01/05/2026 for $189,644.05, and 1,500 shares on 12/22/2025 for $75,000. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio, Inc. reported insider equity activity by its Chief Financial Officer, Dennis Mulroy. On January 7, 2026, 6,700 restricted stock units (RSUs) were settled into an equal number of common shares for no cash consideration, increasing his directly held common stock to 24,367 shares. The RSU award vests in 25% increments annually starting January 7, 2026, subject to continued service.
On January 8, 2026, he sold 2,515 common shares at $44.71 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he directly held 21,852 common shares and 20,100 RSUs.
AnaptysBio (symbol ANAB) disclosed a planned insider sale of common stock under Rule 144. The notice covers 2,515 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 113,703.15. These shares come from restricted stock units acquired from the issuer on 01/08/2026, with cash as the form of payment.
The filing also lists recent sales by Dennis Mulroy over the prior three months. These include 1,908 shares sold on 01/07/2026 for 83,780.28, 3,363 shares on 01/05/2026 for 1,511,166.85, 10,000 shares on 12/22/2025 for 500,000, and 15,725 shares on 12/16/2025 for 705,333.1. The Rule 144 representation confirms the seller states they are not aware of undisclosed material adverse information about the issuer.
AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related tax sale of shares. On January 7, 2026, 5,888 restricted stock units were converted into the same number of shares of AnaptysBio common stock at an exercise price of $0, reflecting that each RSU settles into one share for no cash consideration. After this transaction, Loumeau held 15,045 shares of common stock directly.
On January 8, 2026, he sold 2,210 shares of common stock at a price of $44.71 per share. The filing explains that this sale was executed solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction and was not a discretionary sale. Following the sale, Loumeau directly owned 12,835 shares of common stock and 17,662 RSUs that continue to vest in 25% annual increments starting January 7, 2026, contingent on continued service.
A holder of the issuer’s common stock has filed a Rule 144 notice to sell 2,210 shares through Morgan Stanley Smith Barney, with an aggregate market value of $99,914.10. The filing lists 27,688,470 shares of common stock outstanding and targets an approximate sale date of 01/08/2026 on the NASDAQ market.
The 2,210 shares were acquired on 01/08/2026 as restricted stock units from the issuer, paid for in cash. Over the prior three months, the seller, identified as Eric J. Loumeau, reported multiple sales of the issuer’s common stock, including several transactions of 10,000 shares in December 2025 and additional sales in January 2026, each with disclosed gross proceeds.
AnaptysBio President and CEO Daniel Faga, who is also a director, reported the vesting of 26,838 restricted stock units (RSUs) on January 7, 2026. Each RSU converts into one share of common stock for no cash cost, increasing his directly held common shares to 493,625 and leaving 80,512 RSUs outstanding.
On January 8, 2026, Faga reported selling 14,281 shares of common stock at $44.71 per share. According to the disclosure, this sale was made solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction, and was not a discretionary trade.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
